Yayın:
Utilization and importance of timing of therapeutic plasma exchange in kidney transplantation: A single-center experience

dc.contributor.authorOruc, Aysegul
dc.contributor.authorErsoy, Alparslan
dc.contributor.authorOzkalemkas, Fahir
dc.contributor.authorGul, Cuma Bulent
dc.contributor.authorYigit, Elif
dc.contributor.authorYildiz, Abdulmecit
dc.contributor.buuauthorORUÇ, AYŞEGÜL
dc.contributor.buuauthorERSOY, ALPARSLAN
dc.contributor.buuauthorÖZKALEMKAŞ, FAHİR
dc.contributor.buuauthorGÜL, CUMA BÜLENT
dc.contributor.buuauthorYİĞİT AYHAN, ELİF
dc.contributor.buuauthorYILDIZ, ABDULMECİT
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentİç Hastalıkları Bilim Dalı
dc.contributor.departmentDahili Tıp Bilimleri Bilim Dalı
dc.contributor.orcid0000-0002-0342-9692
dc.contributor.orcid0000-0003-2467-9356
dc.contributor.researcheridNEX-8307-2025
dc.contributor.researcheridAAH-4002-2021
dc.contributor.researcheridDLR-8474-2022
dc.contributor.researcheridA-7063-2018
dc.contributor.researcheridGKK-4397-2022
dc.contributor.researcheridMWP-2826-2025
dc.date.accessioned2025-10-17T11:21:50Z
dc.date.issued2025-06-01
dc.description.abstractIntroduction: Therapeutic plasma exchange (TPE) is a prominent approach for specific conditions among renal transplant candidates and recipients. The indications of TPE, those related to kidney transplantation, are limited, and knowledge and utilization strategies are blurred. Herein, we aimed to review our clinical experience of TPE among renal transplant recipients. Methods: A total of 69 (40.22 +/- 12.29 years, 40 males, 63.8% deceased donor) ABO blood type-compatible kidney transplant recipients who underwent TPE were evaluated between January 2013 and December 2019. Results: A median of 5 (IQR 4-7) TPE sessions was administered at a median duration of 31 (IQR 3-564) days after transplantation. The main indication was a rejection episode. A total of 61 (39.44 +/- 12.22 years, 24 living donor, 10 re-transplant, 37 male) recipients were successfully discharged with a serum creatinine of 1.39 (IQR 1-1.91) mg/dL, and eGFR of 62 (IQR 39-94) ml/min. Comparing the recipients according to TPE timing, early administered 32 (52.5%) recipients with a median of 4 (IQR 4-7) days after transplantation had better graft survival (62.5% vs. 17.2%, p < 0.001), despite higher mortality rates (25% vs.10%, p < 0.001). The rate of graft loss was higher (62.1% vs. 9.4%, p < 0.001) among the recipients who required TPE during the late post-transplant period (756 [IQR 272-1307] days). Conclusion: According to our findings, TPE could provide beneficial effects on graft and patient outcomes, and the timing of TPE could influence its efficiency. Further studies are needed to support our findings.
dc.identifier.doi10.1111/1744-9987.70002
dc.identifier.endpage524
dc.identifier.issn1744-9979
dc.identifier.issue3
dc.identifier.scopus2-s2.0-86000218517
dc.identifier.startpage516
dc.identifier.urihttps://doi.org/10.1111/1744-9987.70002
dc.identifier.urihttps://hdl.handle.net/11452/55646
dc.identifier.volume29
dc.identifier.wos001480833800017
dc.indexed.wosWOS.SCI
dc.language.isoen
dc.publisherWiley
dc.relation.journalTherapeutic Apheresis and Dialysis
dc.subjectAPHERESIS
dc.subjectREJECTION
dc.subjectacute rejection
dc.subjectdesensitization
dc.subjectoutcomes
dc.subjectrenal transplantation
dc.subjecttherapeutic plasma exchange
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectHematology
dc.subjectUrology & Nephrology
dc.subjectHematology
dc.subjectUrology & Nephrology
dc.titleUtilization and importance of timing of therapeutic plasma exchange in kidney transplantation: A single-center experience
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/İç Hastalıkları Bilim Dalı
local.contributor.departmentTıp Fakültesi/Dahili Tıp Bilimleri Bilim Dalı
local.indexed.atWOS
local.indexed.atScopus
relation.isAuthorOfPublicationbd386ce4-0765-45b7-9a09-c10b5eca584a
relation.isAuthorOfPublication3b0ea0d7-f953-4c53-9e92-e260b04f90b4
relation.isAuthorOfPublication6d4676a2-f825-4560-bfa8-c7eb6daf748d
relation.isAuthorOfPublication238d3aec-d833-48a1-b2c7-867f7fe94d52
relation.isAuthorOfPublicationa4ed0e15-a514-46b4-917c-48dbb5dd325e
relation.isAuthorOfPublicatione0f20ddb-a439-4c4a-b87e-d468370abf60
relation.isAuthorOfPublication.latestForDiscoverybd386ce4-0765-45b7-9a09-c10b5eca584a

Dosyalar